content: <html>
  <head>
      <title>regeneron_s8.htm</title>
      <!-- Licensed to: DG3 I Docs, Inc. -->
      <!-- Document Created using EDGARizerAgent 5.3.0.0 -->
      <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
  </head>
  
  
  <body bgcolor="#ffffff">
  <br>
  <br>
  <div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">As filed with the Securities and Exchange Commission on June 13, 2011</font></div>
  
  <div align="right"><font size="2" style="FONT-FAMILY: Times New Roman">Registration No. 333-</font></div>
  
  <hr style="MARGIN-BOTTOM: -6pt; COLOR: black" align="center" size="1" width="100%">
  <hr style="MARGIN-TOP: -6pt; COLOR: black" align="center" size="1" width="100%">
  &#160;
  
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="5" style="FONT-FAMILY: Times New Roman">UNITED STATES<br>
  </font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="5" style="FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION<br>
  </font></font><font size="2" style="FONT-FAMILY: Times New Roman">Washington, DC 20549<br>
  </font><font size="2" style="FONT-FAMILY: Times New Roman">____________________________</font></div>
  
  <div>&#160;</div>
  
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="5" style="FONT-FAMILY: Times New Roman">Form S-8<br>
  </font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">REGISTRATION STATEMENT<br>
  UNDER THE SECURITIES ACT OF 1933<br>
  </font></font><font size="2" style="FONT-FAMILY: Times New Roman">____________________________</font></div>
  
  <div>&#160;</div>
  
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="5" style="FONT-FAMILY: Times New Roman">REGENERON PHARMACEUTICALS, INC.<br>
  </font></font><font size="2" style="FONT-FAMILY: Times New Roman">(Exact name of registrant as specified in its charter)<br>
  </font><font size="2" style="FONT-FAMILY: Times New Roman">____________________________</font></div>
  
  <div>&#160;</div>
  
  <div>
  <table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
  <tr valign="bottom">
  <td nowrap width="56%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">New York</font></font></td>
  <td nowrap width="43%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">13-3444607</font></font></td>
  </tr><tr valign="bottom">
  <td nowrap width="56%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">(State or other jurisdiction of</font></td>
  <td nowrap width="43%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">(I.R.S. Employer</font></td>
  </tr><tr valign="bottom">
  <td nowrap width="56%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">incorporation or organization)</font></td>
  <td nowrap width="43%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Identification No.)</font></td>
  </tr></table>
  </div>
  
  <br>
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">777 Old Saw Mill River Road<br>
  Tarrytown, NY 10591-6707<br>
  </font></font><font size="2" style="FONT-FAMILY: Times New Roman">(Address of principal executive offices) (zip code)</font></div>
  
  <div>&#160;</div>
  
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Regeneron Pharmaceuticals, Inc.<br>
  </font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Second Amended and Restated 2000 Long-Term Incentive Plan<br>
  </font></font><font size="2" style="FONT-FAMILY: Times New Roman">(Full title of the plan)<br>
  </font><font size="2" style="FONT-FAMILY: Times New Roman">____________________________<br>
  </font><font size="2" style="FONT-FAMILY: Times New Roman"><br>
  Murray A. Goldberg</font></div>
  
  <div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">Senior Vice President, Finance and Administration,<br>
  Chief Financial Officer, Treasurer and Assistant Secretary<br>
  Regeneron Pharmaceuticals, Inc.<br>
  </font><font size="2" style="FONT-FAMILY: Times New Roman">777 Old Saw Mill River Road<br>
  Tarrytown, NY 10591-6707<br>
  </font><font size="2" style="FONT-FAMILY: Times New Roman">(Name and address of agent for service)</font></div>
  
  <div>&#160;</div>
  
  <div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">(914) 347-7000<br>
  </font><font size="2" style="FONT-FAMILY: Times New Roman">(Telephone number, including area code, of agent for service)</font></div>
  
  <div>&#160;</div>
  
  <div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">Copies to: </font></div>
  
  <div>&#160;</div>
  
  <div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">Kent A. Coit, Esq.<br>
  Skadden, Arps, Slate, Meagher &amp; Flom LLP<br>
  One Beacon Street<br>
  Boston, MA 02108<br>
  (617) 573-4800</font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Large Accelerated filer&#160;&#160;<font face="Wingdings">x</font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#160; Accelerated filer&#160;&#160;<font face="Wingdings">o</font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#160; Non-Accelerated filer&#160;&#160;<font face="Wingdings">o</font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#160; Smaller reporting company <font face="Wingdings">o</font></font></div>
  
  <div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">____________________________<br>
  <br>
  </font></div>
  
  <hr align="center" noshade size="2" width="100%">
  <div id="PGBRK">
  <div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
  </div>
  
  <br>
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2">CALCULATION OF REGISTRATION FEE<br>
  &#160;<br>
  </font></font>
  
  <table border="0" cellpadding="0" cellspacing="0" width="100%" style="PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
  <tr valign="bottom">
  <td nowrap width="19%" style="BORDER-TOP: #000000 2pt double; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title of Securities<br>
  to be Registered</font></font></td>
  <td nowrap width="20%" style="BORDER-TOP: #000000 2pt double; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Amount to be<br>
  Registered (1)(2)</font></font></td>
  <td nowrap width="20%" style="BORDER-TOP: #000000 2pt double; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Proposed Maximum<br>
  Offering Price<br>
  per Share (3)</font></font></td>
  <td nowrap width="20%" style="BORDER-TOP: #000000 2pt double; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Proposed Maximum<br>
  Aggregate Offering<br>
  Price (3)</font></font></td>
  <td nowrap width="20%" style="BORDER-TOP: #000000 2pt double; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Amount of<br>
  Registration<br>
  Fee (4)</font></font></td>
  </tr><tr valign="bottom">
  <td align="left" nowrap width="19%" style="BORDER-BOTTOM: #000000 2pt double"><font size="2" style="FONT-FAMILY: times new roman"><font size="1" style="FONT-FAMILY: times new roman">Common Stock, par value $0.001 per share</font></font></td>
  <td nowrap width="20%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">12,032,525</font></td>
  <td nowrap width="20%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">$54.80</font></td>
  <td nowrap width="20%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">$659,382,370.00</font></td>
  <td nowrap width="20%" style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">$76,554.29</font></td>
  </tr><tr valign="bottom" style="LINE-HEIGHT: 4pt;">
  <td nowrap width="19%" style="BORDER-BOTTOM: 4px; TEXT-ALIGN: left">&#160;</td>
  <td nowrap width="20%" style="BORDER-BOTTOM: 4px; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
  <td nowrap width="20%" style="BORDER-BOTTOM: 4px; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
  <td nowrap width="20%" style="BORDER-BOTTOM: 4px; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
  <td nowrap width="20%" style="BORDER-BOTTOM: 4px; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
  </tr></table>
  </div>
  
  <br>
  <div>
  <table border="0" cellpadding="0" cellspacing="0" style="">
  <tr>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(1)</font></td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this Registration Statement also covers, in addition to the number of shares stated above, an indeterminate number of additional shares of Common Stock, par value $0.001 per share ("Common Stock") of the Registrant which may become issuable under the Registrant's Second Amended and Restated 2000 Long-Term Incentive Plan (the &#8220;Second Amended 2000 Plan&#8221;) by reason of certain corporate transactions or events, including any stock dividend, stock split or any other similar transaction effected which results in an increase in the number of the Registrant's outstanding shares of Common Stock.</font></td>
  </tr><tr>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(2)</font></td>
  <td nowrap valign="top">&#160;</td>
  <td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">The number of shares being registered includes 32,525 shares (the &#8220;Forfeited Shares&#8221;) previously issued as restricted stock under the Registrant&#8217;s Amended and Restated 2000 Long-Term Incentive Plan and subsequently forfeited and returned to the plan in accordance with its terms.</font></td>
  </tr><tr>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(3)</font></td>
  <td nowrap valign="top">&#160;</td>
  <td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">The fee is based solely on the 12,032,525 shares of Common Stock newly available for issuance under the 2000 Plan and is estimated in accordance with paragraphs (c) and (h) of Rule 457 under the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low sales prices per share of Common Stock as reported on the Nasdaq Global Market on June 10, 2011.</font></td>
  </tr><tr>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(4)</font></td>
  <td nowrap valign="top">&#160;</td>
  <td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">The registration fee has been calculated pursuant to Section 6(b) of the Securities Act by multiplying .00011610 by the proposed maximum aggregate offering price (as computed in accordance with Rule 457 under the Securities Act solely for the purpose of determining the registration fee of the securities registered hereby).</font></td>
  </tr></table>
  </div>
  
  <br>
  <hr align="center" noshade size="2" width="100%">
  <div id="PGBRK">
  <div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
  </div>
  
  <br>
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">EXPLANATORY NOTE </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">At the 2011 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (the &#8220;Company&#8221;) held on June 10, 2011, the Company&#8217;s shareholders approved the Company&#8217;s Second Amended and Restated 2000 Long-Term Incentive Plan (the &#8220;Second Amended 2000 Plan&#8221;), which (1) increased the maximum number of shares of common stock reserved for and available for issuance under the plan by 12,000,000 shares (the &#8220;Additional Shares&#8221;); and (2) extended the term of the plan until December 31, 2016. Shareholder approval of the Second Amended 2000 Plan also constituted re-approval for purposes of Section 162(m) under the Internal Revenue Code of 1986, as amended, of certain performance goals in the plan that may be applied to awards thereunder.</font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>This Registration Statement on Form S-8 is intended to register for issuance under the Second Amended 2000 Plan (i) the Additional Shares and (ii) the Forfeited Shares. </font></div>
  
  <div>&#160;</div>
  
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Part I </font></font></div>
  
  <div>&#160;</div>
  
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Item 1. Plan Information.* </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Item 2. Registrant Information and Employee Plan Annual Information.* </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">*</font></font><font size="2" style="FONT-FAMILY: Times New Roman">The documents containing the information specified in Part I have been sent or given to employees as specified by Rule 428(b)(1). Such documents are not being filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. </font></div>
  
  <div>&#160;</div>
  
  <hr align="center" noshade size="2" width="100%">
  <div id="PGBRK">
  <div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
  </div>
  
  <br>
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Part II</font></font><font size="2" style="FONT-FAMILY: Times New Roman"> </font></div>
  
  <div>&#160;</div>
  
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Item 3. Incorporation of Documents by Reference. </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">The Registrant hereby incorporates by reference into this Registration Statement the following documents filed with the Commission: </font></div>
  
  <div>&#160;</div>
  
  <div>
  <table border="0" cellpadding="0" cellspacing="0" style="">
  <tr>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(a)</font></td>
  <td nowrap><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td width="100%"><font size="2" style="FONT-FAMILY: times new roman">Annual Report on Form 10-K for the year ended December 31, 2010 (filed with the Commission on February 17, 2011);</font></td>
  </tr><tr>
  <td nowrap>&#160;</td>
  <td colspan="3" width="100%">&#160;</td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(b)</font></td>
  <td nowrap>&#160;</td>
  <td width="100%"><font size="2" style="FONT-FAMILY: times new roman">Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 (filed with the Commission on May 3, 2011);</font></td>
  </tr><tr>
  <td nowrap>&#160;</td>
  <td colspan="3" width="100%">&#160;</td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(c)</font></td>
  <td nowrap>&#160;</td>
  <td width="100%"><font size="2" style="FONT-FAMILY: times new roman">Current Report on Form 8-K filed with the Commission on February 28, 2011; Current Report on Form 8-K filed with the Commission on March 10, 2011; Current Report on Form 8-K filed with the Commission on April 18, 2011; Current Report on Form 8-K filed with the Commission on April 26, 2011; and Current Report on Form 8-K filed with the Commission on April 27, 2011.</font></td>
  </tr><tr>
  <td nowrap>&#160;</td>
  <td colspan="3" width="100%">&#160;</td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(d)</font></td>
  <td nowrap>&#160;</td>
  <td width="100%"><font size="2" style="FONT-FAMILY: times new roman">The description of Common Stock contained in the Registration Statement on Form 8-A, filed with the Commission under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), on February 20, 1991, including any amendment or report filed for the purpose of updating such description.</font></td>
  </tr></table>
  </div>
  
  <div>&#160;</div>
  
  <div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.</font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. </font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Item 4. Description of Securities. </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Not applicable. </font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Item 5. Interests of Named Experts and Counsel. </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Not applicable. </font></div>
  
  <div>&#160;</div>
  
  <hr align="center" noshade size="2" width="100%">
  <div id="PGBRK">
  <div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
  </div>
  
  <br>
  <div align="left"><font size="2"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Item 6. Indemnification of Directors and Officers</font><font style="FONT-FAMILY: Times New Roman">.</font></font></div>
  
  <div align="left">&#160;</div>
  
  <div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Article Seven of the Company&#8217;s Restated Certificate of Incorporation provides that, to the fullest extent permitted by the New York Business Corporation Law, no director or officer shall be personally liable to the Company or its shareholders for monetary damages for any breach of fiduciary duty in such capacity. </font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Section 722 of the New York Business Corporation Law permits a corporation to provide for the indemnification of members of its board of directors and its officers against actions or proceedings, or the threat thereof, by or in the right of the corporation. In order to receive indemnification such director or officer must have (i) acted in good faith for a purpose which he reasonably believed to be in the best interests of the corporation and, (ii) in the case of a criminal proceeding, also had no reasonable belief that such conduct was unlawful.</font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Article IV of the Company&#8217;s By-Laws provides that the directors and certain other personnel of the Company shall be indemnified against expenses and certain other liabilities arising out of legal actions brought or threatened against them for their conduct on behalf of the Company, subject to certain qualifications and provided that each such person acted in good faith for a purpose that they reasonably believed to be in the best interests of the Company.</font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>The Company<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>s employment agreement with its President and Chief Executive Officer includes a provision indemnifying him to the fullest extent permitted by law in connection with his serving as an officer or director of the Company. Such indemnification is in addition to and not in lieu of other indemnification rights. The Company maintains directors&#8217; and officers&#8217; liability insurance which insures against liabilities that directors or officers of the Company may incur in such capacities.</font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Item 7. Exemption from Registration Claimed. </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Not applicable. </font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Item 8. Exhibits. </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3">&#160;&#160;&#160;&#160; </font>See Index of Exhibits, which is incorporated herein by reference. </font></div>
  
  <div>&#160;</div>
  
  <hr align="center" noshade size="2" width="100%">
  <div id="PGBRK">
  <div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
  </div>
  
  <br>
  <div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Item 9. Undertakings. </font></font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>The undersigned Registrant hereby undertakes: </font></div>
  
  <div>&#160;</div>
  
  <div>
  <table border="0" cellpadding="0" cellspacing="0" style="">
  <tr>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(1)</font></td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td colspan="3" valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</font></td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td colspan="5" valign="top" width="100%">&#160;</td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(i)</font></td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</font></td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td colspan="5" valign="top" width="100%">&#160;</td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(ii)</font></td>
  <td nowrap valign="top">&#160;</td>
  <td valign="top" width="100%">
  <div><font size="2" style="FONT-FAMILY: times new roman">To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant </font><font size="2" style="FONT-FAMILY: times new roman">to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement;</font></div>
  </td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td valign="top" width="100%">&#160;</td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(iii)</font></td>
  <td nowrap valign="top">&#160;</td>
  <td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;</font></td>
  </tr></table>
  </div>
  
  <br>
  <div align="left"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">provided, however</font></font><font size="2" style="FONT-FAMILY: Times New Roman">, that paragraphs (1)(i) and (1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement. </font></div>
  
  <div>&#160;</div>
  
  <div>
  <table border="0" cellpadding="0" cellspacing="0" style="">
  <tr>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(2)</font></td>
  <td nowrap><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td width="100%"><font size="2" style="FONT-FAMILY: times new roman">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: times new roman">bona fide </font></font><font size="2" style="FONT-FAMILY: times new roman">offering thereof.</font></td>
  </tr><tr>
  <td nowrap>&#160;</td>
  <td colspan="3" width="100%">&#160;</td>
  </tr><tr>
  <td nowrap valign="top">&#160;</td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(3)</font></td>
  <td nowrap>&#160;</td>
  <td width="100%"><font size="2" style="FONT-FAMILY: times new roman">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></td>
  </tr></table>
  </div>
  
  <div>&#160;</div>
  
  <div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">bona fide</font></font><font size="2" style="FONT-FAMILY: Times New Roman"> offering thereof. </font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described under Item 6 above, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </font></div>
  
  <div>&#160;</div>
  
  <hr align="center" noshade size="2" width="100%">
  <div id="PGBRK">
  <div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
  </div>
  
  <br>
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline"><font size="2" style="FONT-FAMILY: Times New Roman">SIGNATURES</font></font></font><font size="2" style="FONT-FAMILY: Times New Roman"> </font></div>
  
  <div>&#160;</div>
  
  <div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tarrytown, State of New York, on June 13, 2011. </font></div>
  
  <div>&#160;</div>
  
  <div>
  <table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
  <tr valign="bottom">
  <td align="left" nowrap width="50%">&#160;</td>
  <td align="left" colspan="2" nowrap width="50%"><font size="2" style="FONT-FAMILY: times new roman">R</font><font size="2" style="FONT-FAMILY: times new roman"><font style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">EGENERON</font> </font><font size="2" style="FONT-FAMILY: times new roman">P</font><font size="2" style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">HARMACEUTICALS</font><font size="2" style="FONT-FAMILY: times new roman">, I</font><font size="2" style="FONT-SIZE: 8pt; FONT-FAMILY: times new roman">NC</font><font size="2" style="FONT-FAMILY: times new roman">.</font></td>
  </tr><tr>
  <td align="left" nowrap width="50%">&#160;</td>
  <td align="left" colspan="2" nowrap width="50%">&#160;</td>
  </tr><tr valign="bottom">
  <td align="left" nowrap width="50%">&#160;</td>
  <td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">By</font></td>
  <td align="left" nowrap width="49%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ Leonard S. Schleifer</font></td>
  </tr><tr valign="bottom">
  <td align="left" nowrap width="50%">&#160;</td>
  <td align="left" nowrap width="1%">&#160;</td>
  <td align="left" nowrap width="49%"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;Leonard S. Schleifer, M.D., Ph.D.</font></td>
  </tr><tr valign="bottom">
  <td align="left" nowrap width="50%">&#160;</td>
  <td align="left" nowrap width="1%">&#160;</td>
  <td align="left" nowrap width="49%"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">President and Chief Executive Officer</font></font></td>
  </tr></table>
  </div>
  
  <br>
  <div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline"><font size="2" style="FONT-FAMILY: Times New Roman">POWER OF ATTORNEY</font></font></font><font size="2" style="FONT-FAMILY: Times New Roman"> </font></div>
  
  <div>&#160;</div>
  
  <div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Leonard S. Schleifer, President and Chief Executive Officer, and Murray A. Goldberg, Senior Vice President, Finance &amp; Administration, Chief Financial Officer, Treasurer, and Assistant Secretary and each of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities therewith, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </font></div>
  
  <div>&#160;</div>
  
  <div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3">&#160;&#160;&#160;&#160; </font>Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated on June 13, 2011. </font></div>
  
  <br>
  <hr align="center" noshade size="2" width="100%">
  <div id="PGBRK">
  <div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
  </div>
  
  <br>
  <div align="left">
  <table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
  <tr valign="bottom">
  <td colspan="2" nowrap width="44%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Signature</font></font></font></font></td>
  <td nowrap width="10%" style="TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Title</font></font></font></font></td>
  </tr><tr valign="bottom">
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ Leonard S. Schleifer</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td align="left" nowrap width="10%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">President, Chief Executive Officer, and</font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Leonard S. Schleifer, M.D., Ph.D.</font></font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center"><font size="2">Director <font style="DISPLAY: inline; FONT-STYLE: italic">(Principal Executive Officer)</font></font></td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160;</td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center">&#160;</td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160; </td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Senior Vice President, Finance &amp;</font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%">&#160;</td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Administration, Chief Financial Officer,</font></font></td>
  </tr><tr valign="bottom">
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ Murray A. Goldberg</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td align="left" nowrap width="10%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: normal">Treasurer, and Assistant Secretary</font></font></font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Murray A. Goldberg</font></font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2">(Principal Financial Officer)</font></font></td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160;</td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center">&#160; </td>
  </tr><tr>
  <td align="left" nowrap valign="bottom" width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ Douglas S. McCorkle</font></td>
  <td align="left" nowrap valign="bottom" width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td align="left" nowrap width="10%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-STYLE: normal; FONT-FAMILY: times new roman">Vice President, Controller, and Assistant</font></font></font></td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%"><font size="2" style="FONT-FAMILY: times new roman">Douglas S. McCorkle</font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Treasurer <font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-FAMILY: times new roman">(Principal Accounting Officer)</font></font></font></td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160;&#160;&#160; </td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center">&#160;</td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160;</td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="right" nowrap width="46%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Executive Vice President, Chief Scientific</font></td>
  </tr><tr>
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ George D. Yancopoulos</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td align="left" nowrap width="10%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td align="right" nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Officer, President, Regeneron Research</font></td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%"><font size="2" style="FONT-FAMILY: times new roman">George D. Yancopoulos, M.D., Ph.D.</font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Laboratories, and Director</font></td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160; </td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center">&#160;</td>
  </tr><tr>
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ P. Roy Vagelos, M.D.</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td align="left" nowrap width="10%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">Chairman of the Board</font></td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%"><font size="2" style="FONT-FAMILY: times new roman">P. Roy Vagelos, M.D.</font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center">&#160;</td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160;&#160; </td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center">&#160;</td>
  </tr><tr>
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ Charles A. Baker</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="10%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">Director</font></td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%"><font size="2" style="FONT-FAMILY: times new roman">Charles A. Baker</font></td>
  <td nowrap width="10%" style="TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center">&#160;</td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">&#160; </font></font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr>
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ Michael S. Brown</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="10%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">Director</font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Michael S. Brown, M.D.</font></font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160; </td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr>
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ Alfred G. Gilman</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="10%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">Director</font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Alfred G. Gilman, M.D., Ph.D.</font></font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160; </td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr>
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ Joseph L. Goldstein</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="10%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">Director</font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Joseph L. Goldstein, M.D.</font></font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160; </td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr>
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ Arthur F. Ryan</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="10%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">Director</font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Arthur F. Ryan</font></font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%">&#160;</td>
  <td nowrap width="10%" style="TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center">&#160;</td>
  </tr><tr>
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ Eric M. Shooter</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="10%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">Director</font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">Eric M. Shooter</font></font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr>
  <td align="left" colspan="2" nowrap width="44%">&#160; </td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr>
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ George L. Sing</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="10%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">Director</font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman"><font size="2" style="FONT-FAMILY: times new roman">George L. Sing</font></font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font style="FONT-FAMILY: times new roman">&#160;</font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td nowrap width="46%" style="TEXT-ALIGN: center">&#160;</td>
  </tr><tr valign="bottom">
  <td align="left" nowrap width="5%" style="BORDER-BOTTOM: black 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/&#160;Christine A. Poon</font></td>
  <td align="left" nowrap width="39%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td align="left" nowrap width="10%" style="PADDING-BOTTOM: 1pt">&#160;</td>
  <td nowrap width="46%" style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"><font size="2">Director</font></td>
  </tr><tr valign="bottom">
  <td align="left" colspan="2" nowrap width="44%"><font size="2" style="FONT-FAMILY: times new roman">Christine A. Poon</font></td>
  <td align="left" nowrap width="10%">&#160;</td>
  <td align="left" nowrap width="46%">&#160;</td>
  </tr></table>
  </div>
  
  <div>&#160;</div>
  
  <hr align="center" noshade size="2" width="100%">
  <div id="PGBRK">
  <div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
  </div>
  
  <br>
  <div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">EXHIBIT INDEX</font></font><font size="2" style="FONT-FAMILY: Times New Roman"> </font></div>
  
  <div style="TEXT-ALIGN: center">&#160;</div>
  
  <div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">Regeneron Pharmaceuticals, Inc. </font></div>
  
  <div>&#160;</div>
  
  <div>
  <table border="0" cellpadding="0" cellspacing="0" width="100%" style="">
  <tr valign="bottom" style="LINE-HEIGHT: 14pt;">
  <td align="left" nowrap width="3%"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Exhibit</font></font></td>
  <td align="left" nowrap width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap width="96%">&#160;</td>
  </tr><tr valign="bottom" style="LINE-HEIGHT: 14pt;">
  <td align="left" nowrap width="3%" style="BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Number</font></font></td>
  <td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td align="left" nowrap width="4%" style="BORDER-BOTTOM: #000000 1pt solid"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Description</font></font></td>
  <td align="left" nowrap width="92%">&#160;</td>
  </tr><tr valign="bottom" bgcolor="silver">
  <td align="right" nowrap valign="top" width="3%"><font size="2" style="FONT-FAMILY: times new roman">4.1</font></td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">Restated Certificate of Incorporation, filed February 11, 2008 with the New York Secretary of State (1)</font></td>
  </tr><tr valign="bottom" bgcolor="white">
  <td align="right" nowrap valign="top" width="3%">&#160;</td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">&#160;</font></td>
  </tr><tr valign="bottom" bgcolor="silver">
  <td align="right" nowrap valign="top" width="3%"><font size="2" style="FONT-FAMILY: times new roman">4.2</font></td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">By-Laws of the Company, currently in effect (amended through November 9, 2007) (2)</font></td>
  </tr><tr valign="bottom" bgcolor="white">
  <td align="right" nowrap valign="top" width="3%">&#160;</td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">&#160;</font></td>
  </tr><tr valign="bottom" bgcolor="silver">
  <td align="right" nowrap valign="top" width="3%"><font size="2" style="FONT-FAMILY: times new roman">5.1</font></td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">Opinion of Skadden, Arps, Slate, Meagher &amp; Flom LLP</font></td>
  </tr><tr bgcolor="white">
  <td align="right" nowrap valign="top" width="3%">&#160;</td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%">&#160;</td>
  </tr><tr valign="bottom" bgcolor="silver">
  <td align="right" nowrap valign="top" width="3%"><font size="2" style="FONT-FAMILY: times new roman">23.1</font></td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">Consent of PricewaterhouseCoopers LLP</font></td>
  </tr><tr bgcolor="white">
  <td align="right" nowrap valign="top" width="3%">&#160;</td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%">&#160;</td>
  </tr><tr valign="bottom" bgcolor="silver">
  <td align="right" nowrap valign="top" width="3%"><font size="2" style="FONT-FAMILY: times new roman">23.2</font></td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">Consent of Skadden, Arps, Slate, Meagher &amp; Flom LLP (contained in the opinion filed as Exhibit 5.1 to this Registration Statement)</font></td>
  </tr><tr valign="bottom" bgcolor="white">
  <td align="right" nowrap valign="top" width="3%">&#160;</td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">&#160;</font></td>
  </tr><tr valign="bottom" bgcolor="silver">
  <td align="right" nowrap valign="top" width="3%"><font size="2" style="FONT-FAMILY: times new roman">24</font></td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">Power of Attorney (included on the signature page of this Registration Statement)</font></td>
  </tr><tr valign="bottom" bgcolor="white">
  <td align="right" nowrap valign="top" width="3%">&#160;</td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">&#160;</font></td>
  </tr><tr valign="bottom" bgcolor="silver">
  <td align="right" nowrap valign="top" width="3%"><font size="2" style="FONT-FAMILY: times new roman">99.1</font></td>
  <td align="left" nowrap valign="top" width="1%">&#160;</td>
  <td align="left" colspan="2" nowrap valign="top" width="96%"><font size="2" style="FONT-FAMILY: times new roman">Second Amended and Restated 2000 Long-Term Incentive Plan</font></td>
  </tr></table>
  </div>
  
  ____________________<br>
  &#160;<br>
  <div>
  <table border="0" cellpadding="0" cellspacing="0" style="">
  <tr>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(1)</font></td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
  <td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Incorporated by reference to Annual Report on Form 10-K for the fiscal year ended December 31, 2007 filed with the Commission on February 27, 2008.</font></td>
  </tr><tr>
  <td colspan="3" valign="top" width="100%">&#160;</td>
  </tr><tr>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(2)</font></td>
  <td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">&#160;</font></td>
  <td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Incorporated by reference to Current Report on Form 8-K filed with the Commission on November 13, 2007.</font></td>
  </tr></table>
  </div>
  
  <div>&#160;</div>
  
  <div>
  <hr align="center" noshade size="2" width="100%">
  </div>
  </body>
  </html>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "regeneron_s8.htm", "description": "INITIAL REGISTRATION STATEMENT FOR SECURITIES TO BE OFFERED TO EMPLOYEES", "secsgml_size_bytes": 60816}]
metadata_filer: {"company-data": {"conformed-name": "REGENERON PHARMACEUTICALS INC", "cik": "0000872589", "assigned-sic": "2834", "irs-number": "133444607", "state-of-incorporation": "NY", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-174863", "film-number": "11908029"}, "business-address": {"street1": "777 OLD SAW MILL RIVER RD", "city": "TARRYTOWN", "state": "NY", "zip": "10591-6707", "phone": "9143477000"}}
text: regeneron_s8.htm
  As filed with the Securities and Exchange Commission on June 13, 2011
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, DC 20549
  ____________________________
  Form S-8
  REGISTRATION STATEMENT
  UNDER THE SECURITIES ACT OF 1933
  ____________________________
  REGENERON PHARMACEUTICALS, INC.
  (Exact name of registrant as specified in its charter)
  ____________________________
  New York
  13-3444607
  (State or other jurisdiction of
  (I.R.S. Employer
  incorporation or organization)
  Identification No.)
  777 Old Saw Mill River Road
  Tarrytown, NY 10591-6707
  (Address of principal executive offices) (zip code)
  Regeneron Pharmaceuticals, Inc.
  Second Amended and Restated 2000 Long-Term Incentive Plan
  (Full title of the plan)
  ____________________________
  Murray A. Goldberg
  Senior Vice President, Finance and Administration,
  Chief Financial Officer, Treasurer and Assistant Secretary
  Regeneron Pharmaceuticals, Inc.
  777 Old Saw Mill River Road
  Tarrytown, NY 10591-6707
  (Name and address of agent for service)
  (914) 347-7000
  (Telephone number, including area code, of agent for service)
  Copies to:
  Kent A. Coit, Esq.
  Skadden, Arps, Slate, Meagher & Flom LLP
  One Beacon Street
  Boston, MA 02108
  (617) 573-4800
  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
  Large Accelerated filer
  x
  Accelerated filer
  o
  Non-Accelerated filer
  o
  Smaller reporting company
  o
  ____________________________
  CALCULATION OF REGISTRATION FEE
  Title of Securities
  to be Registered
  Amount to be
  Registered (1)(2)
  Proposed Maximum
  Offering Price
  per Share (3)
  Proposed Maximum
  Aggregate Offering
  Price (3)
  Amount of
  Registration
  Fee (4)
  Common Stock, par value $0.001 per share
  12,032,525
  $54.80
  $659,382,370.00
  $76,554.29
  (1)
  Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers, in addition to the number of shares stated above, an indeterminate number of additional shares of Common Stock, par value $0.001 per share ("Common Stock") of the Registrant which may become issuable under the Registrant's Second Amended and Restated 2000 Long-Term Incentive Plan (the "Second Amended 2000 Plan") by reason of certain corporate transactions or events, including any stock dividend, stock split or any other similar transaction effected which results in an increase in the number of the Registrant's outstanding shares of Common Stock.
  (2)
  The number of shares being registered includes 32,525 shares (the "Forfeited Shares") previously issued as restricted stock under the Registrant's Amended and Restated 2000 Long-Term Incentive Plan and subsequently forfeited and returned to the plan in accordance with its terms.
  (3)
  The fee is based solely on the 12,032,525 shares of Common Stock newly available for issuance under the 2000 Plan and is estimated in accordance with paragraphs (c) and (h) of Rule 457 under the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low sales prices per share of Common Stock as reported on the Nasdaq Global Market on June 10, 2011.
  (4)
  The registration fee has been calculated pursuant to Section 6(b) of the Securities Act by multiplying .00011610 by the proposed maximum aggregate offering price (as computed in accordance with Rule 457 under the Securities Act solely for the purpose of determining the registration fee of the securities registered hereby).
  EXPLANATORY NOTE
  At the 2011 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (the "Company") held on June 10, 2011, the Company's shareholders approved the Company's Second Amended and Restated 2000 Long-Term Incentive Plan (the "Second Amended 2000 Plan"), which (1) increased the maximum number of shares of common stock reserved for and available for issuance under the plan by 12,000,000 shares (the "Additional Shares"); and (2) extended the term of the plan until December 31, 2016. Shareholder approval of the Second Amended 2000 Plan also constituted re-approval for purposes of Section 162(m) under the Internal Revenue Code of 1986, as amended, of certain performance goals in the plan that may be applied to awards thereunder.
  This Registration Statement on Form S-8 is intended to register for issuance under the Second Amended 2000 Plan (i) the Additional Shares and (ii) the Forfeited Shares.
  Part I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  Item 1. Plan Information.*
  Item 2. Registrant Information and Employee Plan Annual Information.*
  *
  The documents containing the information specified in Part I have been sent or given to employees as specified by Rule 428(b)(1). Such documents are not being filed with the Securities and Exchange Commission (the "Commission") either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
  Part II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  The Registrant hereby incorporates by reference into this Registration Statement the following documents filed with the Commission:
  (a)
  Annual Report on Form 10-K for the year ended December 31, 2010 (filed with the Commission on February 17, 2011);
  (b)
  Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 (filed with the Commission on May 3, 2011);
  (c)
  Current Report on Form 8-K filed with the Commission on February 28, 2011; Current Report on Form 8-K filed with the Commission on March 10, 2011; Current Report on Form 8-K filed with the Commission on April 18, 2011; Current Report on Form 8-K filed with the Commission on April 26, 2011; and Current Report on Form 8-K filed with the Commission on April 27, 2011.
  (d)
  The description of Common Stock contained in the Registration Statement on Form 8-A, filed with the Commission under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on February 20, 1991, including any amendment or report filed for the purpose of updating such description.
  All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.
  Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
  Item 4. Description of Securities.
  Not applicable.
  Item 5. Interests of Named Experts and Counsel.
  Not applicable.
  Item 6. Indemnification of Directors and Officers
  .
  Article Seven of the Company's Restated Certificate of Incorporation provides that, to the fullest extent permitted by the New York Business Corporation Law, no director or officer shall be personally liable to the Company or its shareholders for monetary damages for any breach of fiduciary duty in such capacity.
  Section 722 of the New York Business Corporation Law permits a corporation to provide for the indemnification of members of its board of directors and its officers against actions or proceedings, or the threat thereof, by or in the right of the corporation. In order to receive indemnification such director or officer must have (i) acted in good faith for a purpose which he reasonably believed to be in the best interests of the corporation and, (ii) in the case of a criminal proceeding, also had no reasonable belief that such conduct was unlawful.
  Article IV of the Company's By-Laws provides that the directors and certain other personnel of the Company shall be indemnified against expenses and certain other liabilities arising out of legal actions brought or threatened against them for their conduct on behalf of the Company, subject to certain qualifications and provided that each such person acted in good faith for a purpose that they reasonably believed to be in the best interests of the Company.
  The Company
  '
  s employment agreement with its President and Chief Executive Officer includes a provision indemnifying him to the fullest extent permitted by law in connection with his serving as an officer or director of the Company. Such indemnification is in addition to and not in lieu of other indemnification rights. The Company maintains directors' and officers' liability insurance which insures against liabilities that directors or officers of the Company may incur in such capacities.
  Item 7. Exemption from Registration Claimed.
  Not applicable.
  Item 8. Exhibits.
  See Index of Exhibits, which is incorporated herein by reference.
  Item 9. Undertakings.
  The undersigned Registrant hereby undertakes:
  (1)
  To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)
  To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
  (ii)
  To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
  to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement;
  (iii)
  To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
  provided, however
  , that paragraphs (1)(i) and (1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.
  (2)
  That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
  bona fide
  offering thereof.
  (3)
  To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
  The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
  bona fide
  offering thereof.
  Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described under Item 6 above, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
  SIGNATURES
  Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tarrytown, State of New York, on June 13, 2011.
  R
  EGENERON
  P
  HARMACEUTICALS
  , I
  NC
  .
  By
  /s/ Leonard S. Schleifer
  Leonard S. Schleifer, M.D., Ph.D.
  President and Chief Executive Officer
  POWER OF ATTORNEY
  KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Leonard S. Schleifer, President and Chief Executive Officer, and Murray A. Goldberg, Senior Vice President, Finance & Administration, Chief Financial Officer, Treasurer, and Assistant Secretary and each of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities therewith, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated on June 13, 2011.
  Signature
  Title
  /s/ Leonard S. Schleifer
  President, Chief Executive Officer, and
  Leonard S. Schleifer, M.D., Ph.D.
  Director
  (Principal Executive Officer)
  Senior Vice President, Finance &
  Administration, Chief Financial Officer,
  /s/ Murray A. Goldberg
  Treasurer, and Assistant Secretary
  Murray A. Goldberg
  (Principal Financial Officer)
  /s/ Douglas S. McCorkle
  Vice President, Controller, and Assistant
  Douglas S. McCorkle
  Treasurer
  (Principal Accounting Officer)
  Executive Vice President, Chief Scientific
  /s/ George D. Yancopoulos
  Officer, President, Regeneron Research
  George D. Yancopoulos, M.D., Ph.D.
  Laboratories, and Director
  /s/ P. Roy Vagelos, M.D.
  Chairman of the Board
  P. Roy Vagelos, M.D.
  /s/ Charles A. Baker
  Director
  Charles A. Baker
  /s/ Michael S. Brown
  Director
  Michael S. Brown, M.D.
  /s/ Alfred G. Gilman
  Director
  Alfred G. Gilman, M.D., Ph.D.
  /s/ Joseph L. Goldstein
  Director
  Joseph L. Goldstein, M.D.
  /s/ Arthur F. Ryan
  Director
  Arthur F. Ryan
  /s/ Eric M. Shooter
  Director
  Eric M. Shooter
  /s/ George L. Sing
  Director
  George L. Sing
  /s/ Christine A. Poon
  Director
  Christine A. Poon
  EXHIBIT INDEX
  Regeneron Pharmaceuticals, Inc.
  Exhibit
  Number
  Description
  4.1
  Restated Certificate of Incorporation, filed February 11, 2008 with the New York Secretary of State (1)
  4.2
  By-Laws of the Company, currently in effect (amended through November 9, 2007) (2)
  5.1
  Opinion of Skadden, Arps, Slate, Meagher & Flom LLP
  23.1
  Consent of PricewaterhouseCoopers LLP
  23.2
  Consent of Skadden, Arps, Slate, Meagher & Flom LLP (contained in the opinion filed as Exhibit 5.1 to this Registration Statement)
  24
  Power of Attorney (included on the signature page of this Registration Statement)
  99.1
  Second Amended and Restated 2000 Long-Term Incentive Plan
  ____________________
  (1)
  Incorporated by reference to Annual Report on Form 10-K for the fiscal year ended December 31, 2007 filed with the Commission on February 27, 2008.
  (2)
  Incorporated by reference to Current Report on Form 8-K filed with the Commission on November 13, 2007.